<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800500</url>
  </required_header>
  <id_info>
    <org_study_id>I 165309</org_study_id>
    <secondary_id>NCI-2013-00403</secondary_id>
    <nct_id>NCT01800500</nct_id>
  </id_info>
  <brief_title>Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers</brief_title>
  <official_title>Exploring Current Smokers' Interest in Using Smokeless Tobacco Products Smokeless Tobacco Substitution for Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies interest in smokeless tobacco product as a&#xD;
      substitution for cigarettes in current smokers. Use of smokeless tobacco products may help&#xD;
      people stop smoking. Measuring use of other sources of nicotine for cigarettes under a&#xD;
      variety of different conditions may help determine whether and how much smokers are willing&#xD;
      to use substitutions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Systematically vary price, availability, product type, and information about products to&#xD;
      examine their individual and joint effects on degree of substitution of smokeless products&#xD;
      for cigarettes.&#xD;
&#xD;
      II. Examine the impact of smokeless tobacco (ST) substitution on biomarkers of exposure&#xD;
      (carbon monoxide [CO], cotinine).&#xD;
&#xD;
      III. Explore relationships between ST substitution and measures of mood and health related&#xD;
      quality of life.&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Participants purchase ST products using a fixed rate of product prices once weekly and&#xD;
      record their consumption of ST products and cigarettes smoked daily for 3 weeks.&#xD;
&#xD;
      ARM II: Participants purchase ST products using escalating product prices once weekly and&#xD;
      record their consumption of ST products and cigarettes smoked daily for 3 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty accruing&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of tobacco use accounted for by ST</measure>
    <time_frame>Up to week 5</time_frame>
    <description>Tested using hierarchical linear modeling and generalized estimating equations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of group members that replace at least 50% of baseline cigarette consumption with ST</measure>
    <time_frame>Up to week 5</time_frame>
    <description>Assessed using a Fisher's exact test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in saliva cotinine</measure>
    <time_frame>Up to week 5</time_frame>
    <description>Tested using hierarchical linear modeling and generalized estimating equations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in exhaled alveolar CO</measure>
    <time_frame>Up to week 5</time_frame>
    <description>Tested using hierarchical linear modeling and generalized estimating equations.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>smoking cessation intervention</intervention_name>
    <description>Purchase ST products using a fixed rate of product prices</description>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>smoking cessation intervention</intervention_name>
    <description>Purchase ST products using escalating product prices</description>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ecigarettes</intervention_name>
    <description>Purchase ST products using escalating product prices nicotine replacement therapy</description>
    <arm_group_label>Arm II (escalating ST product prices)</arm_group_label>
    <other_name>ecigarettes, Stonewall, Ariva, Camel Snus, and Marlboro Snus,NRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ecigarettes</intervention_name>
    <description>Purchase ST products using a fixed rate of product prices nicotine replacement therapy</description>
    <arm_group_label>Arm I (fixed rate ST product prices)</arm_group_label>
    <other_name>ecigarettes, Stonewall, Ariva, Camel Snus, and Marlboro Snus, NRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must report currently smoke at least 10 cigarettes per day and been smoking for at&#xD;
             least 1 year&#xD;
&#xD;
          -  Must not be planning to quit smoking in the next 30 days, nor tried to quit in the&#xD;
             last 30 days&#xD;
&#xD;
          -  Must be able to read and speak English&#xD;
&#xD;
          -  Should not concurrently using other tobacco products or nicotine medications&#xD;
&#xD;
          -  Willing to try new tobacco products and substitute other brands of cigarettes&#xD;
&#xD;
          -  Not current participating in any other ongoing research study&#xD;
&#xD;
          -  Must be in good general health&#xD;
&#xD;
          -  Medically eligible to receive nicotine replacement products (based upon the New York&#xD;
             State [NYS] Smokers Quit line eligibility criteria)&#xD;
&#xD;
               -  No history of heart attack or stoke in last 2 weeks&#xD;
&#xD;
               -  No current use of Zyban, bupropion, Wellbutrin, or Chantix/varenicline, or other&#xD;
                  smoking cessation medication&#xD;
&#xD;
               -  No history of chest pains or angina in past month&#xD;
&#xD;
               -  No report of physician diagnosed arrhythmia/irregular heartbeat, fast heartbeat,&#xD;
                  abnormal heart rate, or use of pacemaker&#xD;
&#xD;
               -  No current report of physician diagnosed heart disease/coronary artery disease,&#xD;
                  high blood pressure (systolic blood pressure [SBP] = 160; diastolic blood&#xD;
                  pressure [DBP] = 100), stomach ulcer, diabetes, or taking pills for depression or&#xD;
                  asthma&#xD;
&#xD;
               -  No self-reported chronic dental problems that would interfere with using oral&#xD;
                  products&#xD;
&#xD;
               -  No use of an electronic cigarette (e-cigarette) in the past 30 days&#xD;
&#xD;
               -  No known sensitivity to glycerol, propylene glycol, or glycerin&#xD;
&#xD;
          -  For females, not currently pregnant or breastfeeding; nor planning to become pregnant&#xD;
             during the follow-up interval&#xD;
&#xD;
          -  Prospective participants must also pass screening tests for substance use,&#xD;
             administered at the orientation session, to be entered on study; substance use will be&#xD;
             assessed using a Clinical Laboratory Improvement Amendments (CLIA)-waived 7-drug urine&#xD;
             screen (detecting presence of tetrahydrocannabinol [THC], opiates, amphetamine,&#xD;
             barbiturates, methamphetamine, phencyclidine [PCP], and lysergic acid diethylamide&#xD;
             [LSD]); participants must test negative on all 7 to be put on study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Mahoney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

